Mochida Debuts Japanese Teriparatide Biosimilar
Biosimilar Of Eli Lilly’s Forteo Hits Japanese Market
Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.
